Fairpointe Capital’s Bristol-Myers Squibb BMY Stock Holding History

Fairpointe Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$312K	Sell	4,945 -2,291	-32%	-$143K	0.47%	58
2020 Q4	$449K	Buy	7,236 +100	+1%	+$6.15K	0.08%	61
2020 Q3	$430K	Hold	7,136	–	–	0.07%	62
2020 Q2	$420K	Buy	7,136 +129	+2%	+$7.72K	0.06%	64
2020 Q1	$391K	Sell	7,007 -2,133	-23%	-$130K	0.06%	63
2019 Q4	$587K	Sell	9,140 -1,850	-17%	-$106K	0.05%	61
2019 Q3	$557K	Buy	10,990 +3,200	+41%	+$150K	0.03%	61
2019 Q2	$353K	Buy	7,790 +1,300	+20%	+$60.6K	0.01%	71
2019 Q1	$310K	Buy	6,490 +400	+7%	+$19.9K	0.01%	70
2018 Q4	$317K	Buy	6,090 +1,000	+20%	+$53.7K	0.01%	75
2018 Q3	$316K	Sell	5,090 -1,200	-19%	-$71.2K	0.01%	72
2018 Q2	$348K	Buy	6,290 +1,990	+46%	+$107K	0.01%	70
2018 Q1	$272K	Buy	+4,300	New	+$277K	0.01%	77

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fairpointe Capital's BMY Position: Q1 2021 in Review

Fairpointe Capital reduced its Bristol-Myers Squibb (BMY) stake by 32% in Q1 2021, selling an estimated $143K and leaving 4,945 shares worth $312K. The position accounts for 0.47% of the portfolio, ranked #58.

Fairpointe Capital first reported a position in BMY in Q1 2018 and has held it in 13 quarters since. The position peaked at $587K in Q4 2019. 2,368 funds tracked by Wall St. Rank hold BMY as of Q1 2021.

Fairpointe Capital held 4,945 shares of Bristol-Myers Squibb worth $312K as of Q1 2021.
Fairpointe Capital sold 2,291 Bristol-Myers Squibb shares in Q1 2021, an estimated $143K.
Bristol-Myers Squibb made up 0.47% of Fairpointe Capital's portfolio in Q1 2021, its #58 holding.
Fairpointe Capital first reported a position in Bristol-Myers Squibb in Q1 2018 and has held it in 13 quarters since.
Fairpointe Capital's Bristol-Myers Squibb position peaked at $587K in Q4 2019.
2,368 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2021.

Based on Fairpointe Capital's 13F filing for Q1 2021, filed 13 May 2021.